SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Proteonomix, Inc. (PROT) Retains Numoda Corporation to Provide Clinical Trial Services for Phase 1 Trial With UMK-121 in End-Stage Liver Disease